Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric treprostinil sodium safety and tolerability study in pulmonary arterial hypertension
2023-505082-91-00Phase 3Authorised
- Sponsor
- AOP Health
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by AOP Health. Primary endpoint: Frequency and seriousness of adverse events and adverse drug reactions during first 5 months. Planned start May 2024; status: authorised.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-505082-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505082-91-00.